<DOC>
	<DOCNO>NCT00570479</DOCNO>
	<brief_summary>Retisert implant effective therapy control inflammation patient non-infectious posterior uveitis . One major complication device development elevate intraocular pressure ( IOP ) follow implantation 60 % patient . Glaucoma filtering require 30 % patient 2 year . Anecortave acetate ( AA ) show reduce steroid induce elevated IOP . The purpose study evaluate ability prophylactic anterior juxtascleral depot administration AA prevent Retisert induce elevate IOP .</brief_summary>
	<brief_title>Prophylactic Anecortave Acetate Patients With Retisert Implant</brief_title>
	<detailed_description>Test Article : Anecortave Acetate : 6 % 10 % Sterile Suspension Drug Study Dosage : Patients receive injection ( 0.5 mL , 0.4 mL , 0.2 mL 6 % Anecortave Acetate suspension 0.5 mL 10 % suspension ) study medication every 4 month . Active Ingredients : Anecortave Acetate ( AL-3789 ) Route Administration : Sub-Tenon injection Objective ( ) : To evaluate safety efficacy four dosage ( 50 mg , 30 mg , 24 mg , 12 mg ) Anecortave Acetate ( AA ) prevention steroid-induced intraocular pressure ( IOP ) elevation cause Retisert . Study Population : Approximately 24 patient Structure : Parallel Group Duration Treatment : 3 year Description : Observer-masked study safety efficacy Anecortave Acetate 6 % 10 % administer sub-Tenon injection . Up 24 patient recent implantation Retisert implant give sub-Tenon injection either 0.5 mL , 0.4 mL , 0.2 mL 6 % Anecortave Acetate Sterile suspension 0.5 mL 10 % suspension . Patients receive periodic evaluation re-treatment every 4 month long 3 year . The end point IOP require surgical intervention . An initial assessment efficacy make 18 month . If patient treat low dose develop IOP great 30mHg , eligible receive 50 mg dose . Multicenter : Yes Number Centers : 1 Masking : Observer mask ( IOP-reader ) Method Patient Assignment : Randomization : Yes</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Uveitis , Posterior</mesh_term>
	<mesh_term>Anecortave</mesh_term>
	<criteria>Approximately 24 patient recent implantation Retisert implant meet inclusion/exclusion criterion define enrol study . They identify current future patient clinical practice . Patients must willing sign inform consent form , able make require study visit , able follow instruction . Patient must least 12 year age . Implantation Retisert implant last 12 week . Patient history medical condition would preclude schedule study visit completion study ( i.e. , unstable cardiovascular disease ) Patient insertion scleral buckle study eye . Patient known medical history allergy sensitivity steroid family drug . Patient anticoagulant therapy , exception aspirin antiplatelet therapy . Patient medical history bleed disorder . Patient clinical evidence scleral thinning .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Retisert</keyword>
	<keyword>Uveitis</keyword>
	<keyword>glaucoma</keyword>
</DOC>